MEMANTINE HYDROCHLORIDE (memantine) by Dr. Reddy's Laboratories is n-methyl-d-aspartate (nmda) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of alzheimer's disease. Approved for moderate to severe dementia of the alzheimer's type. First approved in 2010.
Drug data last refreshed 19h ago
N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer's disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA…
The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)
Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis
Worked on MEMANTINE HYDROCHLORIDE at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.